(Q40080622)

17 September 2017

1 reference

title

An overview of the clinical pharmacology of enalapril (English)

1 reference

17 September 2017

1 reference

R. O. Davies

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6099737

5 August 2023

H. J. Gomez

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6099737

5 August 2023

J. D. Irvin

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6099737

5 August 2023

J. F. Walker

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6099737

5 August 2023

language of work or name

English

0 references

publication date

1 January 1984

1 reference

PMC publication ID

1463484

full work available at URL

17 September 2017

https://europepmc.org/articles/PMC1463484

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6099737

https://europepmc.org/articles/PMC1463484?pdf=render

5 August 2023

file format

Portable Document Format

online access status

open access

content deliverer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6099737

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2125.1984.tb02601.x

5 August 2023

1 reference

https://api.crossref.org/works/10.1111/J.1365-2125.1984.TB02601.X

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2125.1984.tb02601.x/fullpdf

5 August 2023

1 reference

https://api.crossref.org/works/10.1111/J.1365-2125.1984.TB02601.X

British Journal of Clinical Pharmacology

5 August 2023

published in

1 reference

17 September 2017

18 Suppl 2

1 reference

17 September 2017

215S-229S

1 reference

Enalapril in the treatment of hypertension with renal artery stenosis

17 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1463484

Haemodynamic, hormonal, and electrolyte effects of enalapril in heart failure

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1463484

Converting-enzyme inhibitor enalapril (MK421) in treatment of hypertension with renal artery stenosis.

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1463484

A new class of angiotensin-converting enzyme inhibitors

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1463484

The physiological disposition and metabolism of enalapril maleate in laboratory animals

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1463484

Plasma enalapril levels and hormonal effects after short- and long-term administration in essential hypertension

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1463484

Enalapril (MK421) and its lysine analogue (MK521): a comparison of acute and chronic effects on blood pressure, renin-angiotensin system and sodium excretion in normal man.

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1463484

Hemodynamic and clinical response to enalapril, a long-acting converting-enzyme inhibitor, in patients with congestive heart failure.

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1463484

Immunoreactive bradykinin and [des-Arg9]-bradykinin in low-renin essential hypertension--before and after treatment with enalapril (MK 421)

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1463484

Enalapril in low-renin essential hypertension

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1463484

Enalapril maleate and a lysine analogue (MK-521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1463484

Enalapril maleate and a lysine analogue (MK-521): disposition in man

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1463484

Pharmacodynamics of converting enzyme inhibition: the cardiovascular, endocrine and autonomic effects of MK421 (enalapril) and MK521

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1463484

Non-sulfhydryl-containing angiotensin-converting enzyme inhibitor (MK421): evidence for role of renin system in normotensive subjects

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1463484

Effect of N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1463484

Cardiac and haemodynamic effects of enalapril

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1463484

Converting enzyme inhibition to identify and treat renin-mediated or sodium-volume related forms of increased peripheral resistance in hypertension and in congestive heart failure

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1463484

Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1463484

Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1463484

Enalapril (MK421) in the treatment of hypertension with renal artery stenosis

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1463484

Disposition of captopril in normal subjects

4 November 2018

1 reference

12 December 2020

Use of first-dose response or plasma renin activity to predict the long-term effect of captopril: identification of triphasic pattern of blood pressure response

1 reference

12 December 2020

Role of prostaglandin in the antihypertensive mechanism of captopril in low renin hypertension

1 reference

12 December 2020

Antihypertensive therapy with MK 421: angiotensin II--renin relationships to evaluate efficacy of converting enzyme blockade

1 reference

12 December 2020

Evaluation of a long-acting converting enzyme inhibitor (enalapril) for the treatment of chronic congestive heart failure

1 reference

12 December 2020

Enalapril maleate (MK-421), a potent, nonsulfhydryl angiotensin-converting enzyme inhibitor: absorption, disposition, and metabolism in man

1 reference

12 December 2020

The renin-angiotensin system in refractory heart failure: clinical, hemodynamic and hormonal effects of captopril and enalapril

1 reference

12 December 2020

Antihypertensive and metabolic effects of a new converting enzyme inhibitor, enalapril

1 reference

12 December 2020

Effects of a new angiotensin-converting enzyme inhibitor, MK 421, in normal men and patients

1 reference

12 December 2020

Reversal of diuretic-induced secondary hyperaldosteronism and hypokalemia by enalapril (MK-421): A new angiotensin-converting enzyme inhibitor

1 reference

12 December 2020

Comparative Antihypertensive Effects of Enalapril Maleate and Hydrochlorothiazide, Alone and in Combination

1 reference

12 December 2020

The Therapeutic use of a new Potassium-Sparing Diuretic, Amiloride, and a Converting Enzyme Inhibitor, Mk-421, in Preventing Hypokalemia Associated with Primary and Secondary Hyperaldosteronism

1 reference

12 December 2020

Endogenous Angiotensin II as a Determinant of Sodium-Modulated Changes in Tissue Responsiveness to Angiotensin II in Normal Man*

1 reference

12 December 2020

Increased renal plasma flow in long-term enalapril treatment of hypertension

1 reference

12 December 2020

Cardiac and hormonal effects of enalapril in hypertension

1 reference

12 December 2020

Enalapril (MK-421), a new angiotensin-converting enzyme inhibitor. Acute and chronic effects in heart failure

1 reference

12 December 2020

Enalapril: A new angiotensin-converting enzyme inhibitor in chronic heart failure: Acute and chronic hemodynamic evaluations

1 reference

12 December 2020

Humoral and Renal Effects of MK-421 (Enalapril) in Hypertensive Subjects

1 reference

12 December 2020

Time Course and Effect of Sodium Intake on Vascular and Hormonal Responses to Enalapril (MK 421) in Normal Subjects

1 reference

12 December 2020

Comparison of oral MK 421 and propranolol in mild to moderate essential hypertension and their effects on arterial and venous vessels of the forearm

1 reference

12 December 2020

Regression of left ventricular hypertrophy from systemic hypertension by enalapril

1 reference

12 December 2020

Long-term clinical experience with enalapril in essential hypertension

1 reference

12 December 2020

Enalapril and autonomic reflexes and exercise performance

1 reference

12 December 2020

The clinical pharmacology of enalapril

1 reference

12 December 2020

Relationship of antihypertensive effect of enalapril to serum MK-422 levels and angiotensin converting enzyme inhibition

1 reference

12 December 2020

Antihypertensive activity of N-[(S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-Ala-L-Pro (MK-421), an orally active converting enzyme inhibitor

1 reference

12 December 2020

Three new long-acting converting-enzyme inhibitors: Relationship between plasma converting-enzyme activity and response to angiotensin I

1 reference

12 December 2020

Contribution of prostaglandins to the antihypertensive action of captopril in essential hypertension

1 reference

12 December 2020

ANTIHYPERTENSIVE EFFECT OF THE NEW ORAL ANGIOTENSIN CONVERTING ENZYME INHIBITOR "MK-421"

1 reference

12 December 2020

Relationship between angiotensin I blockade and antihypertensive properties of single doses of MK-421 and captopril in spontaneous and renal hypertensive rats

1 reference

12 December 2020

Effects of enalapril, a new converting enzyme inhibitor, in hypertension

1 reference

12 December 2020

Temporal enhancement of renin-aldosterone blockade by enalapril, an angiotensin-converting enzyme inhibitor

1 reference

12 December 2020

Altered Fractional Tetrahydroaldosterone Excretion during Pharmacological Blockade and Activation of the Renin-Aldosterone System*

1 reference

12 December 2020

Correlation between angiotensin converting enzyme inhibition and the acute hypotensive response to MK 421 in essential hypertension

1 reference

12 December 2020

Antihypertensive Therapy with MK 4211

7

1 reference

https://api.crossref.org/works/10.1111/J.1365-2125.1984.TB02601.X

Reflex-hemodynamic adjustments and baroreflex sensitivity during converting enzyme inhibition with MK-421 in normal humans

5 August 2023

43

1 reference

https://api.crossref.org/works/10.1111/J.1365-2125.1984.TB02601.X

Mechanism for hypotensive action of angiotensin converting enzyme inhibitors

5 August 2023

47

1 reference

https://api.crossref.org/works/10.1111/J.1365-2125.1984.TB02601.X

5 August 2023

Identifiers

1 reference

17 September 2017

1 reference

PMC publication ID

1463484

17 September 2017

1 reference

PMC publication ID

1463484